

Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023

<https://marketpublishers.com/r/G98C048CAA0EN.html>

Date: April 2018

Pages: 0

Price: US\$ 2,200.00 (Single User License)

ID: G98C048CAA0EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023” report highlights:

Current Market Trends & Development Scenario

Drug Availability, Dosage & Treatment Schedule

Commercially Available Drugs Price Analysis

Global Cancer PARP Inhibitors Clinical Pipeline Overview: 31 Drugs

Clinical & Patent Insight on Commercially Available Drugs: 3 Drugs

Market Segmentation by Drug Patent & Deals

Conventional therapies like surgery, radiotherapy and chemotherapies are currently the dominant form of cancer treatment globally. However, majority of these methods have several limitations with multiple adverse effects which has led to the emergence of much more innovative approach, collectively known as targeted therapies. Targeted cancer therapy segment currently flourishes with several types of therapeutics among which PARP inhibitors have gained immense popularity due to their superior efficacy to conventional therapeutics.

Inhibitors include drugs or substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer. PARP inhibitors are recent entrants in the targeted therapy segment which have gained worldwide popularity as the most common type treatment in certain clinical indications like ovarian cancer and breast cancer.

Poly-ADP Ribose Polymerase or PARP are special proteins that play a key role in assisting damaged cells to repair themselves. The initial clinical testing of PARP inhibitors began nearly a decade ago, following the discovery that these agents in vitro had heightened anticancer activity in cancer cells that harbored BRCA mutations compared to BRCA wild-type cancer cells with intact DNA repair.

Research proved that fault in either of BRCA 1 and BRCA 2 genes have an increased risk of certain types of cancer such as breast cancer, ovarian cancer and prostate cancer. Cells are less likely to repair themselves if there is a fault in one or both of these genes. Blocking PARP with a PARP inhibitor showed impressive results in preventing the proliferation of cancer cells by interfering with their DNA repair mechanism and killing them, thus resulting in a therapeutic outcome.

Currently, there are 3 PARP inhibitors that have been approved for use in patients with suspected or confirmed BRCA-mutated advanced ovarian cancer that has been treated with 3 or more prior lines of chemotherapy. Olaparib (Lynpraza) was the first PARP inhibitor to receive approval in 2014 followed by Rucaparib in 2016 and Niraparib in 2017.

Trends show that the cancer therapy market is steadily shifting from conventional therapeutics to modern therapeutics due to their better safety, efficacy and specificity; thus creating an excellent opportunity for promising therapeutics like PARP inhibitors.

PARP inhibitors have proved to be a commercial success in the modern cancer therapeutic segment. For instance, Lynpraza(Olaparib), marketed by AstraZeneca reported global sales of over US\$ 400 Million in 2017; making it one of the most profitable cancer therapy drugs of the year. Lynpraza sales have more than doubled since its approval which projects an optimistic growth in the future. Olaparib is followed by Niraparib with sales of over US\$ 109 Million during first nine months of commercial launch. Rucaparib – the most recent PARP inhibitor to enter the market is estimated to generate revenue of over US\$ 40 Million by the end of 2018.

The US currently dominates the global PARP inhibitors market leading both in

marketing and research followed by Europe. Involvement of regions like South Korea, Japan and Middle East has led to better market penetration and overall better market growth.

The demand for PARP inhibitors has grown exponentially with the increasing incidence of cancer. Further, their enhanced efficacy in cancer treatment when combined with conventional therapeutics like chemotherapy and radiation therapy has led to an exponential growth in sales; which is further strengthened by a robust clinical pipeline under development. With several favorable factors paving the path for success, PARP inhibitors could be one of the leading cancer therapeutics of the future

KuicK Research Analysis of the global PARP inhibitors market provides an in-depth analysis of the current market scenario, trends, dynamics and recent advances that might have an impact on the PARP inhibitors market. Key data like pricing of drugs, sales and cost of therapy per patient have been used to draw an accurate analysis of the PARP inhibitors market. Finally, KuicK Research analysis of forecast and projections regarding the future of PARP Inhibitors market indicate an exciting opportunity waiting in this highly profitable segment of cancer therapy.

Contents

1. INTRODUCTION TO POLY (ADP-RIBOSE) POLYMERASE INHIBITORS

- 1.1 PARP Inhibitors as Unique Cancer Therapy
- 1.2 Evolutionary Aspects of PARP Inhibitors
- 1.3 Prelude to PARP Proteins & their Inhibitors

2. PARP PROTEINS: AN ATTRACTIVE TARGET FOR DEVELOPING CANCER THERAPEUTICS

- 2.1 Structural Organization of Target Site of PARP Inhibitors
- 2.2 Structural Organization of PARP Inhibitors

3. THERAPEUTIC EXPLOITATION OF ROLE OF PARP PROTEINS IN NORMAL CELLS & CANCER CELLS

- 3.1 Significance of PARP Proteins in Normal Cells
- 3.2 Significance of PARP Proteins in Tumorigenesis: Affecting Cell Division & DNA Repair
- 3.3 PARP Inhibitors: Distinct Modes of Action for Eliminating Cancer Cells

4. GLOBAL POLY (ADP-RIBOSE) POLYMERASE INHIBITORS CLINICAL PIPELINE OVERVIEW

5. COMMERCIALY AVAILABLE POLY (ADP-RIBOSE) POLYMERASE INHIBITORS (PARP INHIBITORS) AS CANCER MONOTHERAPY

- 5.1 Olaparib
 - 5.1.1 Availability, Dosage & Treatment Schedule
 - 5.1.2 Price Analysis
- 5.2 Rucaparib
 - 5.2.1 Availability, Dosage & Treatment Schedule
 - 5.2.2 Price Analysis
- 5.3 Niraparib
 - 5.3.1 Availability, Dosage & Treatment Schedule
 - 5.3.2 Price Analysis
- 5.4 Promising PARP Inhibitors in Clinical Pipeline: Efficiency, Dosage & Expected Price
 - 5.4.1 Talazoparib

5.4.2 Veliparib

6. GLOBAL PARP INHIBITOR CANCER THERAPY CURRENT MARKET SCENARIO

- 6.1 PARP Inhibitor Market Outline
- 6.2 Market Segmentation by Patent
- 6.3 Market Segmentation by Drug Sales
- 6.4 Market Trends

7. PARP INHIBITORS WITH CONVENTIONAL CANCER THERAPY: EFFICACY, DOSAGE & PRICE ANALYSIS

- 7.1 PARP Inhibitors with Chemotherapy
 - 7.1.1 Temozolomide
 - 7.1.2 Platinum Salts
 - 7.1.3 Taxanes
 - 7.1.4 Gemcitabine
 - 7.1.5 Topoisomerase Inhibitors/Poisons
- 7.2 PARP Inhibitors in Combination with Radiotherapy

8. IMPROVED EFFICACY OF PARP INHIBITORS BY MODERN CANCER THERAPIES

- 8.1 Combination of PARP Inhibitors & Targeted Therapies
 - 8.1.1 PARP Inhibitors with EGFR Inhibitors
 - 8.1.2 PARP Inhibitors with VEGFR Inhibitors
 - 8.1.3 PARP Inhibitors with PI3K/mTOR Inhibitors
 - 8.1.4 PARP Inhibitors with Trastuzumab
 - 8.1.5 Anti-endocrine agents
 - 8.1.6 HSP90 Inhibitors
 - 8.1.7 IGF-1R & HDAC Inhibitors
- 8.2 PARP Inhibitors in Combination with Immunotherapies

9. FACTORS DRIVING GLOBAL PARP INHIBITORS MARKET

- 9.1 Consecutive Approvals of Several PARP Inhibitors & Anticipated Approvals in the Nearby Future
- 9.2 Strong clinical Pipeline
- 9.3 Large Patient Base

9.4 Commercial Success of Approved PARP Inhibitors

10. GLOBAL PARP INHIBITOR MARKET CHALLENGES

10.1 Scientific Limitations and the Number of Side Effects

10.2 Tedious approval process

11. GLOBAL PARP INHIBITORS MARKET FUTURE FORECAST

11.1 PARP Inhibitors in the Pipeline: Shaping the Future of Ineffectively Treated Cancer

11.1.1 PARP Inhibitors for Prostate Cancer

11.1.2 PARP Inhibitors for Lung Cancer

11.1.3 PARP Inhibitors in Pancreatic Cancer

11.2 Market Opportunity

12. GLOBAL CANCER PARP INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

12.1 Preclinical

12.2 Clinical

12.3 Phase-I

12.4 Phase-I/II

12.5 Phase-II

12.6 Phase-III

13. MARKETED CANCER PARP INHIBITORS CLINICAL INSIGHT BY COMPANY & INDICATION

13.1 Olaparib (Lynparza)

13.2 Niraparib (Zejula)

13.3 Rucaparib (Rubraca)

14. COMPETITIVE LANDSCAPE

14.1 2X Oncology

14.2 Abott Laboratories

14.3 Cephalon

14.4 Checkpoint Therapeutics

14.5 Eisai Co. Ltd

- 14.6 IMPACT Therapeutics
- 14.7 Jeil Pharmaceuticals
- 14.8 KuDOS Pharmaceuticals
- 14.9 Kyowa Hakko Kirin
- 14.10 Lead Therapeutics
- 14.11 Shanghai De Novo Pharmatech

List Of Figures

LIST OF FIGURES

Figure 1-1: History & Evolution of PARP Inhibitors

Figure 1-2: Biochemistry & Biological Functions Of Poly ADP-Ribosylation Reaction Mediated by Poly (ADP-Ribose) Polymerase (PARP) Enzymes

Figure 2-1: Structural Organization of PARP-1 & PARP-2 Enzymes

Figure 3-1: PARP Proteins in DNA Damage Repair Mechanism

Figure 3-2: Importance of PARP in DNA Repair Mechanism in Normal Cells

Figure 3-3: Dual Action of PARP inhibition for Cancer Treatment

Figure 4-1: Global – Cancer PARP Inhibitors Pipeline by Phase (%), 2018 till 2023

Figure 4-2: Global – Cancer PARP Inhibitors Pipeline by Phase (Number), 2018 till 2023

Figure 4-3: Global – Cancer PARP Inhibitors Pipeline by Phase (%), 2018 till 2023

Figure 4-4: Global – Cancer PARP Inhibitors Pipeline by Phase (Number), 2018 till 2023

Figure 5-1: Progression Free Survival in Patients with Platinum-Sensitive, Relapsed, BRCA-mutant Ovarian Cancer by Using a PARP Inhibitor for 30 Months

Figure 5-2: Olaparib - Available Concentrations (mg), 2018

Figure 5-3: Olaparib - Dosage Analysis (mg/Day)

Figure 5-4: Olaparib - 150mg & 100mg Tablet Dosage Analysis (mg/12 hour) By Tablet Concentration

Figure 5-5: Olaparib - 50mg Tablet Dosage Analysis (Number of Capsules/Day)

Figure 5-6: Olaparib - Price Analysis by Type (US\$/Unit), 2018

Figure 5-7: Olaparib - Price Analysis by Type (US\$/Packet), 2018

Figure 5-8: Olaparib - Average Price Analysis for Breast & Ovarian Cancer Treatment (US\$), 2018

Figure 5-9: Olaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Reoccurrent BRCA Mutated Population (US\$), 2018

Figure 5-10: Olaparib - Total Cost Analysis for Ovarian Cancer Maintenance Therapy for Reoccurrent BRCA Mutated Population (US\$), 2018

Figure 5-11: Olaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Platinum Sensitive Germline BRCA Mutated Cancer Population (US\$), 2018

Figure 5-12: Rucaparib - Available Concentrations of Drug (mg)

Figure 5-13: Rucaparib - Dosage Analysis (mg/Day), 2018

Figure 5-14: Rucaparib - 300mg & 200mg Tablet Dosage Analysis (mg/12 hour) By Tablet Concentration

Figure 5-15: Rucaparib - Price Analysis (US\$), 2018

Figure 5-16: Rucaparib - Average Price Analysis for Reoccurrent BRCA Mutated Cancer Treatment (US\$), 2018

Figure 5-17: Rucaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Reoccurent BRCA Mutated Population (US\$), 2018

Figure 5-18: Rucaparib - Total Cost Analysis for Maintenance Therapy for Reoccurent BRCA Mutated Cancer Population (US\$), 2018

Figure 5-19: Niraparib - Dosage Analysis (mg/Day)

Figure 5-20: Niraparib - Price Analysis (US\$), 2018

Figure 5-21: Niraparib - Average Price Analysis for Breast & Ovarian Cancer Treatment (US\$), 2018

Figure 5-22: Niraparib - Maintenance Therapy Cost Analysis for Germline BRCA Mutated Cancer Population (US\$), 2018

Figure 5-23: Niraparib - Maintenance Therapy Cost Analysis for Non - Germline BRCA Mutated Cancer Population (US\$), 2018

Figure 5-24: Niraparib - Complete Cancer Treatment Cost Analysis

Figure 5-25: Talazoparib – Upcoming Concentration (mg), 2018

Figure 5-26: Talazoparib - Expected Price Analysis by Concentration (US\$), 2018

Figure 5-27: Veliparib - Treatment Course Analysis indicated in Clinical Trials

Figure 5-28: Veliparib - Dosage Analysis indicated in Clinical Trials (mg)

Figure 5-29: Overall Survival in Patients with Breast Cancer Treated with Carboplatin + Paclitaxel with Veliparib v/s without Veliparib (Months)

Figure 6-1: Global – Lynparza (Olaparib) Patent Approval & Expiration Year by Drug Form, 2018

Figure 6-2: Lynparza (Olaparib) - Number of Granted Patents & Applications, 2018

Figure 6-3: US - Lynparza (Olaparib) Patent Analysis by Number, 2018

Figure 6-4: Global – Lynparza (Olaparib) Patent Analysis by Approved Drug Formulations, 2018

Figure 6-5: Global – Rubraca (Rucaparib) Patent Approval & Expiration Year, 2018

Figure 6-6: Rucaparib (Rubraca) - Number of Granted Patents & Applications, 2018

Figure 6-7: Global – Zejula (Niraparib) Patent Approval & Expiration Year, 2018

Figure 6-8: Zejula (Niraparib) - Granted Patents & Applications, 2018

Figure 6-9: Global – Lynparza (Olaparib) Sales (US\$ Million), 2015-2017

Figure 6-10: Global – Rubraca (Rucaparib) Sales (US\$ Milion), 2017

Figure 6-11: Global – Zejula (Niraparib) Sales (US\$ Million), Q1'2017 & Q2'2017

Figure 6-12: Global – PARP Inhibitors End Users (Number of Patients/Year), 2018

Figure 7-1: Tolerable Dosage of Rucaparib & Temozolomide Combination Therapy in Clinical Trials for Advanced Malignancy (mg/m²)

Figure 7-2: Study of Veliparib + Temozolomide Showing Improved Survival of Patients with Metastatic Melanoma (Months)

Figure 7-3: Estimated Glioblastoma Treatment Cost for Temozolomide + PARP Inhibitor Therapy, (US\$/Cycle)

Figure 7-4: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (mg/Day & mg/m²/Day)

Figure 7-5: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (Administeration/Cycle)

Figure 7-6: Olaparib & Paclitaxel Combination Therapy Cost Analysis for Metastatic Gastric Cancer (US\$/Cycle)

Figure 7-7: Overall Survival of Patients with Metastatic Gastic Cancer with Paclitaxel Chemotherapy vs Combination Therapy with Olaparib (Months)

Figure 7-8: Overall Survival in Patients with Triple-Negative Breast Cancer Treated with Gemiciabine & Carboplatin Chemotherapy vs Combination Therapy with Iniparib (Months)

Figure 8-1: Overall Progression Free Survival in Patients with Recurrent Platinum-Sensitive High-Grade Serous or Endometrioid Ovarian Cancer Treated with Cediranib + Olaparib v/s Olaparib Monotherapy (Months), 2018

Figure 8-2: Olaparib & Cediranib Combination Therapy Dosage Analysis as per Clinical Trials (mg/Day)

Figure 9-1: Expected Approval of PARP Inhibitors in the Nearby Future

Figure 11-1: US - PARP Inhibitor Market Opprtunity in Ovarian Cancer by Patient Base Undergoing Treatment

Figure 11-2: US - PARP Inhibitor Market Opprtunity in Breast Cancer by Patient Base Undergoing Treatment

List Of Tables

LIST OF TABLES

Table 11-1: Ongoing Clinical Trials of PARP Inhibitor Combination Therapy for Prostate Cancer

COMPANIES MENTIONED

2X Oncology, Abbott Laboratories, Cephalon, Checkpoint Therapeutics, Eisai Co. Ltd, IMPACT Therapeutics, Jeil Pharmaceuticals, KuDOS Pharmaceuticals, Kyowa Hakko Kirin, Lead Therapeutics, Shanghai De Novo Pharmatech

I would like to order

Product name: Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023

Product link: <https://marketpublishers.com/r/G98C048CAA0EN.html>

Price: US\$ 2,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G98C048CAA0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

